TGF-β regulates sclerostin expression via the ECR5 enhancer
- 31 March 2012
- journal article
- Published by Elsevier BV in Bone
- Vol. 50 (3), 663-669
- https://doi.org/10.1016/j.bone.2011.11.016
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator FunctionOnline Journal of Public Health Informatics, 2011
- Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanismJournal of Bone and Mineral Research, 2011
- Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseProceedings of the National Academy of Sciences of the United States of America, 2010
- Where Wnts Went: The Exploding Field of Lrp5 and Lrp6 Signaling in BoneJournal of Bone and Mineral Research, 2009
- Disruption of BMP Signaling in Osteoblasts Through Type IA Receptor (BMPRIA) Increases Bone MassJournal of Bone and Mineral Research, 2008
- BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathwayDevelopment, 2008
- Dickkopf‐1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasisThe Prostate, 2008
- Control of the SOST Bone Enhancer by PTH Using MEF2 Transcription FactorsJournal of Bone and Mineral Research, 2007
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001